{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:55:24Z","timestamp":1792684524668,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21AI105959"],"award-info":[{"award-number":["R21AI105959"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["RO1AI104854"],"award-info":[{"award-number":["RO1AI104854"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P30 AI045008"],"award-info":[{"award-number":["P30 AI045008"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.vaccine.2018.11.076","type":"journal-article","created":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T07:43:19Z","timestamp":1544600599000},"page":"664-669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["A trivalent gC2\/gD2\/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5540-2459","authenticated-orcid":false,"given":"Lauren M.","family":"Hook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sita","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Dubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7034-7689","authenticated-orcid":false,"given":"Jessica","family":"Flechtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey M.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.11.076_b0005","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1056\/NEJMoa011915","article-title":"Glycoprotein-D-adjuvant vaccine to prevent genital herpes","volume":"347","author":"Stanberry","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.11.076_b0010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1103151","article-title":"Efficacy results of a trial of a herpes simplex vaccine","volume":"366","author":"Belshe","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.11.076_b0015","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.282.4.331","article-title":"Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV vaccine study group","volume":"282","author":"Corey","year":"1999","journal-title":"Jama"},{"key":"10.1016\/j.vaccine.2018.11.076_b0020","first-page":"1","article-title":"A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model","author":"Awasthi","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.11.076_b0025","doi-asserted-by":"crossref","first-page":"e1006141","DOI":"10.1371\/journal.ppat.1006141","article-title":"An HSV-2 trivalent vaccine is immunogenic in rhesus macaques and highly efficacious in guinea pigs","volume":"13","author":"Awasthi","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2018.11.076_b0030","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.4049\/jimmunol.158.4.1763","article-title":"Mechanism of complement inactivation by glycoprotein C of herpes simplex virus","volume":"158","author":"Kostavasili","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.11.076_b0035","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1128\/JVI.80.8.4038-4046.2006","article-title":"Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulin M antibody","volume":"80","author":"Hook","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.11.076_b0040","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/infdis\/162.2.331","article-title":"Glycoprotein C of herpes simplex virus type 1 prevents complement-mediated cell lysis and virus neutralization","volume":"162","author":"Harris","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.11.076_b0045","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.1128\/JVI.01130-14","article-title":"Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes","volume":"88","author":"Awasthi","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.11.076_b0050","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1128\/JVI.63.11.4479-4488.1989","article-title":"A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G","volume":"63","author":"Frank","year":"1989","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.11.076_b0055","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1128\/JVI.02509-10","article-title":"The herpes simplex virus 1 IgG fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo","volume":"85","author":"Lubinski","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.11.076_b0060","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.coviro.2014.02.006","article-title":"Status of prophylactic and therapeutic genital herpes vaccines","volume":"6","author":"Awasthi","year":"2014","journal-title":"Curr. Opin. Virol"},{"key":"10.1016\/j.vaccine.2018.11.076_b0065","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1128\/JVI.07107-11","article-title":"Immunodominant \u201casymptomatic\u201d herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals","volume":"86","author":"Dasgupta","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.11.076_b0070","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1128\/JVI.05194-11","article-title":"Discovery of potential diagnostic and vaccine antigens in herpes simplex virus 1 and 2 by proteome-wide antibody profiling","volume":"86","author":"Kalantari-Dehaghi","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.11.076_b0075","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/nature05818","article-title":"Exploiting the defensive sugars of HIV-1 for drug and vaccine design","volume":"446","author":"Scanlan","year":"2007","journal-title":"Nature"},{"issue":"Pt 12","key":"10.1016\/j.vaccine.2018.11.076_b0080","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1099\/0022-1317-73-12-3099","article-title":"Carbohydrate determinant NeuAc-Gal beta (1\u20134) of N-linked glycans modulates the antigenic activity of human immunodeficiency virus type 1 glycoprotein gp120","volume":"73","author":"Bolmstedt","year":"1992","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2018.11.076_b0085","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/nsmb.2594","article-title":"Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120","volume":"20","author":"Kong","year":"2013","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.vaccine.2018.11.076_b0090","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.1128\/JVI.02599-07","article-title":"Blocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and E","volume":"82","author":"Hook","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.11.076_b0095","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/289373a0","article-title":"Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation","volume":"289","author":"Wiley","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2018.11.076_b0100","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.virol.2014.07.018","article-title":"Identification of novel virus-specific antigens by CD4(+) and CD8(+) T cells from asymptomatic HSV-2 seropositive and seronegative donors","volume":"464\u2013465","author":"Long","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.11.076_b0105","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1128\/JVI.03163-13","article-title":"Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs","volume":"88","author":"Awasthi","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.11.076_b0110","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1016\/j.vaccine.2005.04.034","article-title":"Implications for herpes simplex virus vaccine strategies based on antibodies produced to herpes simplex virus type 1 glycoprotein gC immune evasion domains","volume":"23","author":"Chang","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.076_b0115","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00544-14","article-title":"Repertoire of epitopes recognized by serum IgG from humans vaccinated with herpes simplex virus type 2 glycoprotein D","author":"Whitbeck","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.11.076_b0120","doi-asserted-by":"crossref","first-page":"12612","DOI":"10.1128\/JVI.01930-14","article-title":"Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans","volume":"88","author":"Cairns","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.11.076_b0125","doi-asserted-by":"crossref","first-page":"12639","DOI":"10.1128\/JVI.77.23.12639-12645.2003","article-title":"Blocking immune evasion as a novel approach for prevention and treatment of herpes simplex virus infection","volume":"77","author":"Judson","year":"2003","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18316396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18316396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T01:45:32Z","timestamp":1694483132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18316396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0264410X18316396"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.076","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A trivalent gC2\/gD2\/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}